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Copyright © 2009 JCBN Summary Endoscopic submucosal dissection (ESD) has the advantage over endoscopic
mucosa resection, permitting removal of gastrointestinal neoplasms en bloc, but is associated
with relatively high risk of complications. Indications for early gastric cancer (EGC) are
expanded: mucosal cancer without ulcer findings irrespective of tumor size; mucosal cancer
with ulcer findings ≤3 cm in diameter; and minute submucosal invasive cancer ≤3 cm in size.
The indications for early esophageal cancer (EEC) are the tumors confined to the two-third
layer of the lamina propria. The EEC lesions spreading more than three-quarter of circum-
ference of the esophagus are at frequent risk of stenosis. The procedures include marking,
submucosal injection, circumferential mucosal incision and exforiation of the lesion along the
submucosal layer. Complete ESD can achieve a large one-piece resection, allowing precise
histological assessment to prevent recurrence. Clinical outcomes of gastric and esophageal
ESD have been promising, and the prognosis of EGC patients treated by ESD is likely to be
excellent, though further longer follow-up studies are warranted. Notification of perforation
risk is essential in particular for esophageal ESD. Bleeding during ESD can be managed with
coagulation forceps, and postoperative bleeding may be reduced with routine use of the
stronger acid suppressant, proton pump inhibitors.
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Introduction
Early gastric cancer (EGC) is defined as gastric cancer
that is confined to the mucosa or submucosa (T1 cancer),
irrespective of the presence of regional lymph node
metastases [1]. Currently, almost 10,000 cases of EGC are
being detected every year in Japan, corresponding to 40% to
50% of all gastric cancers [2]. Endoscopic mucosal resection
(EMR) is widely accepted as a standard treatment for EGC
with nominal risk of lymph node metastasis, as it is mini-
mally invasive, safe, and convenient [3, 4]. The conven-
tional EMR is associated with a high risk of local recurrence
in such cases, especially when resections are accomplished
in multiple segments or the margins are not clear [5].
Endoscopic submucosal dissection (ESD) has been
developed to dissect directly along the submucosal layer
using an insulation-tipped diathermy knife (IT knife) [6, 7].
Earlier studies have been documented the advantage of
ESD over conventional EMR for removing larger or ulceratedH. Isomoto et al.
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EGC lesions in an en bloc manner [8–10]. Thus, ESD allows
precise histological assessment of the resected specimens,
and it may prevent residual disease and local recurrence
[4, 5, 11]. More recently, ESD has been successfully applied
for early esophageal cancer (EEC) including squamous cell
carcinoma and Barrett’s adenocarcinoma [12–14].
Although the short-term results of ESD are promising, a
higher risk of procedure-related complications remains
unresolved in this innovative procedure [5, 9, 10, 12–15].
The complications of endoscopic resection for EGC include
abdominal pain, bleeding, and perforation [16]. Bleeding is
the most common complication, occurring in up to no less
than 7% of patients undergoing ESD [16]. On the other
hand, accumulating evidence has documented that bleeding
occurs in 1.2–11.6% of EGC patients treated by EMR [16].
Proton pump inhibitors (PPIs) and H2-receptor antagonists
(H2RAs) have a significant effect on preventing bleeding
from the ulcer and facilitating the ulcer healing [17]. ESD
creates larger artificial ulcers with greater risks of bleeding,
but whether the stronger acid suppressant, PPIs would
reduce incidence of the complication is unknown.
In this review, we sought to outline the endoscopic indica-
tions, techniques, clinical outcomes and management of the
complications of ESD in the upper gastrointestinal tract, in
the era of PPIs, the first choice drug for acid-peptic diseases.
Indications of ESD
EMR is widely accepted as a standard treatment for
EGC with nominal risk of lymph node metastasis, as it is
minimally invasive, safe, and convenient [3, 4]. However,
the snaring procedure is not reliable for lesions larger than
20 mm in diameter or lesions with ulcer findings [5, 8]. The
conventional EMR is associated with a high risk of local
recurrence in such cases, especially when resections are
not accomplished en bloc or the margins are not clear [5].
At present, the guideline criteria for EMR, which were
established by the Japanese Gastric Cancer Association,
have been generally accepted, and they state that: (1)
elevated EGCs less than 2 cm in diameter and (2) small
(≤1 cm) depressed EGCs without ulceration are absolutely
indicated for EMR [18]. At the same time, these lesions must
be differentiated adenocarcinoma confined to the mucosa
with no lymphatic or vascular involvement. However, it has
been observed clinically that the accepted indications for
EMR can be too strict, leading to unnecessary surgery [5, 16].
Recently, Gotoda et al. analyzed more than 5,000 EGC
patients who underwent gastrectomy with meticulous D2
level lymph node dissection; they provided important infor-
mation on the risks of lymph node metastasis, wherein
differentiated gastric cancers (well and moderately differen-
tiated tubular adenocarcinoma and papillary adenocarcinoma)
with no lymphatic-vascular involvement, correlating with a
nominal risk of lymph node metastasis, were defined [19].
Thus, they proposed the expanded criteria for endoscopic
resection: (1) mucosal cancer without ulcer findings irre-
spective of tumor size; (2) mucosal cancer with ulcer find-
ings ≤3 cm in diameter; and (3) minute (<500 μm from the
muscularis mucosae) submucosal invasive cancer ≤3c m  i n
size [4, 5]. These groups of patients have been shown to
have no risk or a lower risk of lymph node metastasis
compared with the risk of mortality from surgery. Nowadays,
en bloc resection of the tumors that fit the expanded criteria
is achievable with ESD. In fact, attempts to expand the
indications for ESD to treat EGC are currently underway in
many Japanese institutes.
EEC involving the epithelium (m1: carcinoma in situ) or
the lamina propria (m2) are candidates for endoscopic
therapies including ESD and EMR, because no lymph node
metastasis have been reported in EEC confined to these
layers [20]. For EEC invading the muscularis mucosa
(m3), the lymph node metastasis rate is reported as 9%, and
for cancer with minute submucosal invasion the rate is
increased with 19% [21]. Therefore, for patients unwilling
for esophagectomy or patients with comorbid diseases,
endoscopic treatment may be a relative indication for m3 or
sm1 cancer. EEC spreading more than three-quarter of
circumference of the esophagus are not absolutely indicated
even if the invasion depth is limited to m1 or m2 [20, 21].
Although such lesions can be removed en bloc with ESD,
they are considered as the relative indication. Nevertheless,
intensive balloon dilatations or tentative stent insertion
may prevent stricture [12, 20, 22]. Previous studies have
suggested a satisfactory prognosis after EMR, and EMR has
been used for the treatment of EEC or high-grade dysplasia
[23]. Despite its efficacy, this method is sometimes associated
with local recurrences, especially when lesions larger than
20 mm are resected in a piecemeal manner. In turn, ESD
allows en bloc resection for EEC, irrespective of size. In
fact, successful resection of large esophageal cancers by
ESD has been reported in relatively small numbers of the
case series [12, 23]. When the efficacy of ESD for smaller
lesions ≤20 mm was compared with that of EMR, ESD was
found to be the best endoscopic resection method even for
the smaller EEC [23].
Endoscopic treatment is an alternative to esophagectomy
in Barrett’s esophagus patients with superficial adenocarci-
noma due to the nominal risk of lymph node involvement or
distal metastases [20]. For Barrett’s adenocarcinomas, EMR
has limitations with respect to the resectable tumor size; in
many cases, piecemeal resection is unavoidable and has
been occasionally linked to local recurrence [20]. Recently,
ESD has been used to remove the esophagogastric junction
tumors including Barrett’s neoplasms with promising results
[13, 14]. However, there are no available data about nodal
metastases from the large numbers of surgically resectedESD and PPI
Vol. 44, No. 3, 2009
207
cases of Barrett’s adenocarcinoma at an early stage. Indeed,
there is no or nominal risk of nodal metastasis for the intra-
mucosal Barrett’s adenocarcinoma, but the tumors with
massive sm involvement are associated with considerable
risk for metastatic disease [20]. There is no consensus
whether one should apply to Barrett’s adenocarcinomas
confined within the upper third of the submucosa the same
criteria for gastric epithelial neoplasms or esophageal
squamous cell neoplasms [20].
ESD Technique
ESD, which is performed with special endoscopic knives
such as IT knife, has been developed for en bloc resection
with a standard single-channel gastroscope [6]. This innova-
tive technique has the great advantage for resections of
larger and/or ulcerated lesions in one-piece over EMR [5, 6].
Under written informed consent, the ESD procedures, which
are described previously in detail [24], are done with the
following steps. EGC is first identified and demarcated
using white-light endoscopy and chromoendoscopy with
indigo-carmine solution, and then marking around the
lesions is carried out with spotty cautery. A 10% glycerin
plus 5% fructose in 0.9% saline solution (Glyceol; Chugai
Pharmaceutical Co., Tokyo, Japan) was injected into the
submucosal layer to lift the mucosa. A circumferential
mucosal incision is made around the lesion using the IT knife
(Olympus Optical Co., Tokyo, Japan). A high-frequency
generator (ICC200; ERBE Elektromedizin GmbH, Tübingen,
Germany) is used during incision of the mucosa set the Endo
cut mode at Effect 3, output 80W. The ceramic ball at the tip
of IT knife prevents perforation of the muscle layer. Then,
submucosal dissection is performed for exforiation of the
lesion using the IT-knife and/or the Hook-knife (Olympus
Optical Co.) in technically difficult situations. The solution
can be injected into the submucosa at any time to raise and
confirm the submucosal layer. A cap attachment (Olympus
Optical Co.) is frequently useful for creating countertraction,
making it easier to exfoliate the submucosal tissue directly.
Complete endoscopic submucosal dissection can achieve a
large one-piece resection. The ESD procedures for EEC are
performed in the similar way to those for EGC with several
modifications for the esophagus. A mucosal incision is made
circumferentially around the lesion using the FlushKnife
(Fujinon-Toshiba ES System Co., Omiya, Japan). A sub-
mucosal injection solution is prepared by mixing 1 volume
of Suvenyl (a 10 mg/mL solution of 1900 kD hyaluronic
acid in physiologic saline, Chugai Pharmaceutical Co.) with
3 volumes of the Glyceol. The mucosal incision employs the
ENDOCUT mode, effect 2 (output 60W). The distal half of
the mucosal incision is completed first. The proximal half is
incised after the submucosal layer is dissected slightly, as
described in the following steps. Before incising all the way
around the markings, dissection of the submucosa is started
beneath the area where the mucosal incision is made. This is
done to avoid flattening the remaining area lifted by the
cushioning solution as time passes. The submucosal dissec-
tion is done using the Flush knife and/or the Hook knife,
under the forced coagulation mode (output 40W), until the
lesion is detached. With this highly skilled technique, cura-
tive resection (en bloc resection with the tumor-free lateral/
vertical margins) was achieved in circumference for a case
of semicircular esophageal squamous cell carcinoma,
approximately 7 cm wide (Fig. 1). Even if the invasion depth
of EECs spreading more than three-quarter of circumference
of the esophagus is limited to m1 or m2, they are considered
as the relative indication due to the unavoidable stricture.
To control bleeding during ESD or to prevent possible
bleeding from visible vessels in the artificial ulcer immedi-
ately after the resection, a hemostatic forceps (Coagrasper,
Fig. 1. Endoscopic submucosal dissection in a case of semicircular esophageal squamous cell carcinoma, approximately 7 cm wide.
Choromoendoscopy with an iodine solution revealed the iodine unstained area spreading three-quarter of circumference of the
esophagus (A). En bloc removal of the lesion was achieved in circumference (B). Resected specimen removed by ESD showed
complete resection with the tumor-free margin (C).H. Isomoto et al.
J. Clin. Biochem. Nutr.
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Olympus Optical Co.) is employed in the soft coagulation
mode (60W for EGC and 50W for EEC).
All patients are sedated by intravenous injection of 5–
7.5 mg diazepam (Cercine; Takeda Pharmaceutical Co.,
Osaka, Japan) and 15 mg pentazocine (Pentazin, Daiichi-
Sankyo Pharmaceutical Co., Tokyo, Japan), and 2.5 mg
diazepam was additionally given for sedation as needed
throughout the procedure.
The excised specimens were fixed in 10% buffered
formalin, paraffin-embedded, sectioned perpendicularly at
2-mm intervals and stained with hematoxylin and eosin.
Macroscopic appearance, histological type, the tumor size,
the depth of invasion, the presence of ulcerative changes,
lymphatic and vascular involvement, and tumor involve-
ment to the lateral and vertical margins are assessed. En bloc
resection refers to a resection in one-piece. When the lesion
had to be removed in multiple segments, the piecemeal-
resected specimens were reconstructed as completely as
possible. Resections were deemed curative when removal is
achieved with tumor-free lateral and vertical margins. By
definition, there should be no lymphatic and vascular
involvement. In addition, there should be no submucosal
invasion deeper than 500 μm from the muscularis mucosae
for EGC or be limited to the m1 or m2 in cases of EEC.
Management of Complications during ESD and
Clinical Course after ESD
The complications of endoscopic resection for EGC
include pain, bleeding, and perforation [16]. Pain after resec-
tion is typically mild. Bleeding is the most common compli-
cation, occurring in up to 1.2–11.6% of patients undergoing
standard EMR and in up to 7% of patients undergoing ESD
[16]. During ESD, minor bleeding is commonly seen but can
be successfully treated by grasping the bleeding vessels with
Coagrasper as described above. Endoclips are sometimes
needed for aggressive bleeding. Thereafter, a sodium
alginate powder (Alto, Kaigen Co., Osaka, Japan) or
sucrose-aluminum hydroxide gel (Chugai Pharmaceutical
Co.) is sprayed onto the artificial ulcer base [22]. Delayed
bleeding, manifested by hematemesis or melena at 0–30
days after the procedure, may require emergent endoscopy.
In the era of the stronger acid suppressant, PPIs, in order to
prevent postoperative bleeding and promote ulcer healing,
the standard dose of PPI is administered for patients with
EGC or EEC treated by ESD. Even large ulcers after ESD
have recently been reported to heal within 8 weeks after
resection under the antacid treatment [16]. Nevertheless,
most delayed bleeding (75%) occurs within 12 h after the
procedure [16], and patients are typically placed on fasting
for 1 day, followed by liquid diet on the second day, and a
soft diet for another 3 days. The patients remain hospitalized
for at least 8 days. In cases of semicircular or circumferential
EECs, intraluminal stenosis of the esophagus often occurs
postoperatively [22], and such patients should undergo
repeated (i.e., twice per week in our hospital) mechanical
dilation with the specialized balloon catheter (Boston
Scientific Japan Co., Tokyo, Japan), and hence, would be
discharged several weeks after ESD.
PPIs and H2RAs have a significant effect on preventing
bleeding from the ulcer and facilitating the ulcer healing
after gastric EMR [17,  25]. ESD creates larger artificial
ulcers with greater risks of bleeding, but there is little infor-
mation on whether PPIs would reduce incidence of the
complication [25]. In order to investigate whether a PPI,
rabeprazole (Eisai Pharmaceutical Co., Tokyo, Japan) more
effectively prevents bleeding after ESD for EGC, Uedo et al.
conducted a prospective randomized controlled trial, where
a total of 143 patients with EGC who underwent ESD were
randomly assigned to either rabeprazole 20 mg/day (PPI
group) or cimetidine 800 mg/day (H2RA group) on the day
before ESD and continued for 8 weeks [25]. Bleeding
occurred in 4 patients in the PPI group and 11 in the H2RA
group; multivariate analysis revealed that treatment with the
PPI significantly reduced the risk of bleeding (adjusted
hazard ratio 0.47, 95% confidence interval, 0.22–0.92). One
delayed perforation was experienced in the H2RA group.
Thus, PPI may prevent bleeding from the ulcer created after
ESD more effectively than H2RA. In our hospital, patients
receive oral lansoprazole (Takeda Pharmaceutical Co.)
30 mg/day for 2 weeks prior to ESD in cases of EGC with
ulcer finding. On the day of ESD, the PPI is given intra-
venously at the same dose every 12 h for 2 days, and then
oral lansoprazole are continued with 30 mg/day for 8 weeks.
Perforation is rare with EMR but is seen not so un-
commonly with ESD. The risk of perforation during ESD
for EGC is about 4% in a large series from the Japanese
Cancer institute [16]. Gastric perforation during endoscopic
resection can be conservatively treated by complete endo-
scopic closure with endoclips (HX-600-090, Olympus
Optical Co.) without peritoneal dissemination of the cancer
cells. In addition, nasogastric suction is applied, and a broad
spectrum antibiotic is efficiently given for 2–3 days. If
abdominal fullness due to air leakage from the perforated
lesion is severe, decompression of the pneumoperitoneum
by puncture needle must be performed. On the other hand, a
delayed perforation due to the artificial ulcers following
ESD is rare but may require surgical intervention.
More recently, we conducted statistical analysis for the
clinicopathological factors related to ESD-related bleeding
and perforation in the largest consecutive series with more
than 700 EGCs [24]. The procedure-related bleeding after
ESD was defined as bleeding that required transfusion or
surgical intervention, or bleeding that caused the hemo-
globin level to fall by 2 g/dL [15]. Perforation was diag-
nosed endoscopically or by the presence of free air on anESD and PPI
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abdominal plain radiograph or computed tomogram (CT).
The procedure-related bleeding was rarely seen in 1.8% of
the cases. All hemorrhagic episodes were successfully
treated by endoscopic clipping or coagulation. Perforations
related to ESD occurred in 4.5% and could also be managed
by conservative medical treatment after endoscopic closure
with clipping. The bleeding was not associated with any
clinicopathological characteristics including age, gender,
tumor size, tumor location, and macroscopic appearance of
EGC while the location and tumor size had significant
impact on the ESD-related perforation. Gotoda et al.
reported that tumors located in the upper third of the
stomach and those with ulcer findings were at significantly
higher risk of perforation [16].
There have been few reports on the complications of ESD
in the esophagus. Fujishiro et al. reported that perforation
occurred in 6.9% (4/58) patients with esophageal squamous
cell neoplasms during the ESD, whereas there was no
evidence of significant bleeding [12]. The patients with
the complication were managed by conservative medical
treatments after endoscopic closure of the perforation. Here,
notification of risk of perforation in esophageal ESD is
essential, since it may cause severe or even life-threatening
conditions including mediastinal emphysema and media-
stinitis [12].
The incidence of local recurrence of EGC after EMR
varies between 2% and 35% [5]. On the other hand, local
recurrence of gastric cancer after ESD would be nominal
when curative resection is achieved, whereas about 10% of
patients with non-curative resection had local recurrence
[24]. This implies that EGC patients with non-curative ESD
require close follow-up surveillance for cancer recurrence
for at least 2 years, as the recurrent tumors developed 13
to 24 months after ESD in the follow-up study [24].
Preliminary outcomes of ESD for EGC documented 14
(6.2%) metachronous lesions among 225 EGCs at unknown
stages following ESD [11]. The incidence of metachronous
gastric cancer varies from 1.8% to 8.1% after EMR [26],
and, thus, the necessity for continued surveillance for
recurrent and/or new lesions as well as metastatic disease is
an intrinsic drawback of endoscopic therapies, irrespective
of curability. As for the follow-up in our hospital, endo-
scopic examinations were scheduled at 1, 3, 6, and 12
months after ESD and then annually thereafter. Biopsy
specimens during each follow-up endoscopy were taken
from the treatment-related scar or any other suspicious
abnormalities to assess the presence of local recurrent tumor
or metachronous cancer of the stomach. To detect lymph
node and distant metastases, contrast-enhanced CT and
ultrasound sonography of the abdomen and chest X-rays
were performed annually.
Outcomes of ESD
In the recent largest case series with EGC, en bloc resec-
tion was achieved in 94.9% (559/589) with ESD. 550 of 581
lesions (94.7%) were deemed to have undergone curative
resection [24].  En bloc resection of ESD provides much
higher curative resection rates than piecemeal resection.
Using logistic regression analysis, we have assessed the
impact of various factors on the curability of ESD. On
univariate basis, piecemeal resection and ulcer findings
interfered with curative resection. Oka et al. also showed
that ulceration prevented complete removal of EGCs,
notably in lesions larger than 21 mm [8]. A similar tendency
was seen in EGC patients treated by ESD for recurrent
EGC after previous EMR [27]. Nevertheless, multivariate
analysis revealed that en bloc resection was the sole signifi-
cant contributor to curative ESD [24]. Oda et al. reported
that upper and middle location, tumor size more than
21 mm, and positive ulcer findings were associated with
piecemeal resection [15]. Oka et al. reported a marked
decrease in en bloc resection rates from 92.9% for EGC
without ulcer findings to 19.2% for tumors with ulceration
[9]. Only 9.1% of the ulcerative lesions greater than 21 mm
in size were resected en bloc [ 9]. On the multivariate
analysis, there was a significant association of tumor size
with lesion resectability. Collectively, larger and/or ulcera-
tive EGCs could be at higher risk of piecemeal resection;
therefore, their treatment requires a high level of expertise
and experience.
Despite the increasing use of ESD for EGC, the long-term
clinical outcomes have not been fully evaluated. The 3-year
overall survival after ESD seems excellent, with the rate
being nearly 99% [24]. In a multicenter study of endoscopic
resection for EGC, Oda et al. reported a comparable 3-year
overall survival between the EMR and ESD groups (99.7%
and 98.5%, respectively) [28]. The 5-year survival rate after
ESD reached 97.1%, which was equivalent to those after
EMR documented in previous reports [26, 29]. Of note, both
the 3-year and 5-year disease-specific survival rates after
ESD were 100% [24], similar to those after EMR in 12
major Japanese institutions [26]. In general, EGC has
excellent clinical outcomes, with 10- and 20-year survival
rates after gastrectomy with removal of lymph nodes as
high as 95% [26]. Confirmation of whether ESD can equal
surgery will require further long-term prospective studies.
As for esophageal ESD, 41 cases of esophageal neo-
plasms consisting of 26 superficial squamous cell carci-
nomas, 13 severe dysplasia and 2 intramucosal Barrett’s
adenocaricnomas underwent ESD in our hospital between
April 2006 and October 2008. On the whole, en bloc resec-
tion was achieved in all patients, and the rate of en bloc with
the tumor-free lateral/vertical margins was 88% (36/41).
There was no perforation and bleeding, but intramuralH. Isomoto et al.
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stricture occurred in 4 of the 41 cases. All the 4 lesions
extended more than three-quarter of circumference of the
esophagus. The 4 patients with non-curative resection
underwent additional treatment (3 radical surgery and 1
chemoradiation), the one with severe dysplasia positive
for the lateral margin has been under follow-up without local
recurrence. Fujishiro et al. reported that the rate of en bloc
resection was 100% (58/58) for esophageal squamous cell
neoplasms, and en bloc resection with tumor-free lateral/
basal margins was achieved in 78% (45/58) [12]. Of 40
lesions occurring in 31 patients fulfilling the criteria of
node-negative tumors (mean follow-up, 17 months), one
lesion resected by en bloc resection with nonevaluable
tumor-free lateral margins recurred locally 6 months after
ESD, which was treated successfully by a second ESD
procedure.
For 30 lesions of esophagogastric tumors including
Barrett’s adenocarcinoma treated by ESD, the en bloc
resection with the tumor-free lateral/vertical margins was
achieved in 97% (29/30) [13]. Histological evaluation of the
resected specimens revealed five cases of angiolymphatic
invasion and five cases of submucosal invasion deeper than
500 μm. Local recurrence was not observed in any patient
during follow-up (mean 14.6 months, range 6–31 months)
in their study. In another study, the en bloc resection rate
was 100% in 25 superficial adenocarcinoma located at the
esophagogastric junction. Seventeen lesions (72%) were
judged as curative resection with the tumor-free lateral/
vertical margins and showed no local or distant recurrence
during a median follow-up period of 30.1 months [14]. Thus,
ESD can be safely and effectively performed for the
esophagogastric junction tumors, albeit the study numbers
of these preliminary studies were limited.
Conclusions
Endoscopic resection of EGC and EEC is well established
as a standard therapy in Japan and is increasingly becoming
accepted and regularly used in the other countries. ESD, an
innovative application modality of EMR, has been developed
to allow the resection of larger lesions in an en bloc manner;
the earlier results so far have been promising in EGC, EEC
and esophagogastric junction tumors including Barrett’s
adenocarcinoma. It is feasible to assess the histopathological
curability of the resected specimens precisely, reducing
recurrence. ESD still has relatively high complication rates;
notification of perforation risk is essential in particular when
performing esophageal ESD. Bleeding during ESD can be
managed by endoscopic closure with endoclips, and delayed
bleeding is rare with the use of oral and/or intravenous PPIs.
The relatively long-term outcomes may be excellent in EGC
after ESD. Nevertheless, continued surveillance is necessary
for recurrent tumors in cases of non-curative resection and
for metachronous cancers even after curative ESD.
Abbreviations
ESD, endoscopic submucosal dissection; EMR, endo-
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